Conference Day One
8:25 am Chair’s Opening Remarks
8:30 am Industry Leaders’ Fireside Chat: What’s Next for T-Cell Receptor Therapies?
Synopsis
- Appreciating the wealth of TCR therapy advances and exploring the data to secure clinical validation
- Examining the range of TCR modalities and their respective targeting benefits
- Discussing the advances in allogeneic TCR approaches to determine the future directions for TCR therapies
9:30 am Case Study Spotlight: Introducing Innovations at Each Step of TCR Therapy Development
Synopsis
- Effective, specific and safe antigen identification using an in silico screening program to knock out unwanted epitopes
- Utilizing a high throughput robotics platform to find donor TCRs for any antigen/ HLA combination
- Creating enhanced inducible TCR products with precision pairing technology and switch receptors to arm against the tumor microenvironment
Optimizing Tumor-Specific Targeting & Exploring Novel Antigens to Move Beyond Current Targets
10:00 am Revealing Efficient Approaches to Uncover Solid Tumor Specific Targets
Synopsis
- Advancing target discovery tools and technology to discover effective targets beyond PRAME and MAGE-A4
- Identifying antigen targets that are specific to solid tumors to prevent off-target toxicity
- Validating targets and TCRs to maximize therapeutic outcome and overcome risks of cross-reactivity and safety
10:30 am Morning Refreshment Break & Speed Networking
11:30 am Exploiting Gamma Delta TCR Targeting to Enable Safe & Effective Cell Therapies for Solid Tumors
Synopsis
- γδ TCR are naturally selected, recognize surface targets like antibodies on transformed “stressed” tumor tissue but not healthy tissue and are not HLA dependent
- Gadeta’s TEG platform (T-cells engineered with a defined γδ TCR) magnifies the potential therapeutic activity of γδ T-cells
- The talk will highlight Gadeta’s clinical and development programs
12:00 pm Targets & Off-Targets of TCR-based Therapies
Synopsis
- Liabilities of TCR-based therapies
- Methods to identify targets
- Constructs to overcome hurdles
12:30 pm Targeting Dark Antigens to Ensure Tumor Specificity
Synopsis
- Utilizing technology to discover solid tumor specific dark matter
- Assessing dark antigen density on tumor tissue to evaluate targeting potential
- Ensuring the dark matter is not expressed in healthy tissue to mediate tumor specificity
1:00 pm Lunch Break & Networking
Differentiating TCR Therapy Modalities to Identify & Harness their Unique Advantages
2:00 pm Panel: Comparing the Characteristics of TCR-T Cell Therapies & TCR Bispecifics (& More!) to Reaffirm their Unique Benefits
Synopsis
- Comparing relative affinities, potencies and safety considerations of T-cell therapies and bispecifics
- Assessing indications and patients where each TCR modality could be best suited to treat
- What other modalities can TCR therapies venture into in the future?
2:45 pm Developing Effective TCR-like Antibody Based T-Cell Engagers for Therapeutics Use
Synopsis
- Technology enables rapid isolation of selective high affinity antibodies against peptide-MHC complexes
- Utilizing the M-gager® platform to make highly specific and effective pMHC targeting T-cell engagers
- Current focus on cancer testis antigens and other highly prevalent cancer targets
3:15 pm Afternoon Break & Refreshments
3:45 pm Advancing Development of TCR-T Cell Therapy Alongside TCR Bispecifics Modalities
Synopsis
- Discovery and validation of TCR molecules suited to adoptive cell therapy of bispecific modalities
- Distinguishing attributes of each TCR modality to identify advantages and areas of strength
- Sharing insights from the clinical ACTengine® trial
4:15 pm Unlocking Allogeneic TCR Therapies to Pursue Wider Treatment Capability
Synopsis
- Achieving a durable allogeneic response to promote tumor persistence
- Preventing graft versus host disease to inhibit toxicity in vivo
- Ensuring TCR scalability to addressing off-the-shelf manufacturing
4:45 pm Close of Conference Day One
